StockData
Aclaris Therapeutics, Inc. logo

Aclaris Therapeutics, Inc. (ACRS) stock

ACRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30138% above fair value
$3.38−0.23 (-6.24%)

Close on Nov 17, 2026Market cap $497.53MP/E –Yield –

Aclaris Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

No total debt figures for Aclaris Therapeutics

Aclaris Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Aclaris Therapeutics figures

See a number that looks wrong?